Pacira BioSciences, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Pacira BioSciences, Inc. (PCRX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PCRX insiders buying or selling?
In the last 12 months, Pacira BioSciences, Inc. insiders reported 0 open-market purchases ($0) and 13 sales ($2.1M) — net selling of $2.1M. Since January 2018, Trabud has recorded 189 Form 4 filings for PCRX: 12 buys ($871.6K) and 177 sells ($116.1M).
Source: SEC EDGAR Form 4
What stands out
- No Pacira BioSciences, Inc. insider made an open-market purchase in the last 12 months; the 13 reported open-market sales totaled $2.1M.
Key Statistics (January 2018 – Oct 9, 2026)
Total Form 4 filings
189
SEC EDGAR
Insider filers
27
Insider buys (12)
$871.6K
Insider sells (177)
$116.1M
Insider sentiment
Net sellingNet insider flow of $115.3M in net selling since January 2018, and $2.1M in net selling over the last 12 months.
Recent PCRX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | Lauren Riker | Senior Vice President, Finance | Sale | 6.0K | $36.32 | $217.9K | SEC ↗ |
| Aug 18, 2026 | Jonathan Slonin | Chief Medical Officer | Sale | 3.0K | $23.23 | $70.6K | SEC ↗ |
| Jun 13, 2026 | Lauren Riker | Senior Vice President, Finance | Sale | 6.1K | $23.50 | $143.7K | SEC ↗ |
| Jun 5, 2026 | Kristen Williams | Chief Administrative Officer | Sale | 10.3K | $22.27 | $228.5K | SEC ↗ |
| Apr 25, 2026 | Shawn Cross | Chief Financial Officer | Sale | 12.9K | $25.16 | $325.6K | SEC ↗ |
| Apr 23, 2026 | Shawn Cross | Chief Financial Officer | Sale | 12.1K | $25.09 | $302.6K | SEC ↗ |
| Mar 19, 2026 | Jonathan Slonin | Chief Medical Officer | Sale | 3.3K | $22.82 | $74.4K | SEC ↗ |
| Mar 19, 2026 | Mark Froimson | Director | Sale | 500 | $21.81 | $10.9K | SEC ↗ |
| Feb 3, 2026 | Lauren Riker | Senior Vice President, Finance | Sale | 4.0K | $20.81 | $83.2K | SEC ↗ |
| Feb 3, 2026 | Kristen Williams | Chief Administrative Officer | Sale | 13.1K | $20.53 | $269.7K | SEC ↗ |
| Jan 6, 2026 | Lauren Riker | Senior Vice President, Finance | Sale | 1.4K | $24.24 | $34.3K | SEC ↗ |
| Nov 19, 2025 | Jonathan Slonin | Chief Medical Officer | Sale | 4.0K | $24.09 | $95.4K | SEC ↗ |
| Nov 13, 2025 | Shawn Cross | Chief Financial Officer | Sale | 12.1K | $22.09 | $266.4K | SEC ↗ |
| Sep 8, 2025 | Abraham Ceesay | Director | Sale | 2.4K | $27.19 | $64.0K | SEC ↗ |
| Aug 11, 2025 | Marcelo Bigal | Director | Sale | 4.9K | $23.67 | $116.3K | SEC ↗ |
| Jun 5, 2025 | Lauren Riker | Senior Vice President, Finance | Sale | 5.6K | $26.21 | $146.2K | SEC ↗ |
| Jun 5, 2025 | Kristen Williams | Chief Administrative Officer | Sale | 14.4K | $26.24 | $377.2K | SEC ↗ |
| Jan 6, 2025 | Jonathan Slonin | Chief Medical Officer | Sale | 879 | $18.40 | $16.2K | SEC ↗ |
| Dec 16, 2024 | Daryl Gaugler | Chief Operating Officer | Sale | 500 | $19.76 | $9.9K | SEC ↗ |
| Sep 14, 2024 | Daryl Gaugler | Chief Operating Officer | Sale | 500 | $12.86 | $6.4K | SEC ↗ |
| Aug 19, 2024 | Marcelo Bigal | Director | Purchase | 1.5K | $13.25 | $20.0K | SEC ↗ |
| Aug 19, 2024 | Laura Brege | Director | Purchase | 1.0K | $12.81 | $12.8K | SEC ↗ |
| Aug 14, 2024 | Michael J. Yang | Director | Purchase | 2.0K | $12.90 | $25.8K | SEC ↗ |
| Aug 13, 2024 | Frank D. Lee | Chief Executive Officer | Purchase | 8.3K | $12.10 | $100.0K | SEC ↗ |
| Aug 13, 2024 | Marcelo Bigal | Director | Purchase | 3.4K | $12.01 | $40.8K | SEC ↗ |
Showing the 25 most recent of 189 Form 4 filings for Pacira BioSciences, Inc..
Most active PCRX insiders
- Lauren Riker33 filings
- Kristen Williams22 filings
- David M Stack19 filings
- Jonathan Slonin11 filings
- Max Reinhardt10 filings
Ask anything about PCRX insider activity
Use Trabud's AI agent to query Pacira BioSciences, Inc.'s Form 4 history in plain English — "Show me PCRX CEO purchases this year" or compare it against any other ticker.
Open the AI agentPCRX insider trading FAQ
Are Pacira BioSciences, Inc. insiders buying or selling?
In the last 12 months, Pacira BioSciences, Inc. insiders reported 0 open-market purchases ($0) and 13 sales ($2.1M) — net selling of $2.1M. Since January 2018, Trabud has recorded 189 Form 4 filings for PCRX: 12 buys ($871.6K) and 177 sells ($116.1M). Over the full record that is net selling of $115.3M.
How many insiders trade PCRX stock?
27 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Pacira BioSciences, Inc.. The most recent filing was accepted on Oct 9, 2026.
Where does Trabud get PCRX insider trading data?
All PCRX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.